Are Krebs Biochem latest results good or bad?

Krebs Biochemicals & Industries has reported its financial results for the quarter ending June 2025, which highlight a challenging operational landscape. The company's net sales for the quarter were Rs 5.48 crore, reflecting a significant decline of 57.49% year-on-year, marking the lowest sales figure in the last five quarters. This indicates a persistent downward trend in revenue generation.
On a somewhat positive note, the operating profit before depreciation, interest, and taxes (PBDIT) reached Rs -2.09 crore, which is the highest figure recorded in the last five quarters, suggesting potential improvements in operational efficiency. Additionally, the debtors turnover ratio improved to 866.40 times, representing the best performance over the last five half-yearly periods, indicating that the company is settling its debts more quickly.

However, the profit after tax (PAT) for the latest six months was reported at Rs -13.59 crore, a decline of 53.42% year-on-year, reflecting ongoing profitability challenges. Furthermore, the debt-equity ratio has risen to -1.45 times, indicating increased borrowing to support operations, which may put additional strain on liquidity.

Overall, Krebs Biochemicals & Industries has faced significant challenges in its latest financial results, with a notable adjustment in its evaluation reflecting these operational difficulties.